BIOMAT Database Logo BIOMAT Database Logo

Thalidomide as an inhibitor of tumor necrosis factor-alpha production: a word of caution. 1999

A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012871 Skin Diseases Diseases involving the DERMIS or EPIDERMIS. Dermatoses,Skin and Subcutaneous Tissue Disorders,Dermatosis,Skin Disease
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide.
February 1999, Biological & pharmaceutical bulletin,
A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
March 1991, The Journal of experimental medicine,
A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
Enhancement of phorbol ester-induced production of tumor necrosis factor alpha by thalidomide.
March 1994, Biochemical and biophysical research communications,
A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
Anti-tumor necrosis factor agents and COVID-19: A word of caution.
September 2020, Journal of clinical and translational research,
A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells.
November 2003, The Journal of investigative dermatology,
A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
Characterization of a small molecule inhibitor of tumor necrosis factor-alpha production.
October 2010, Chinese medical journal,
A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro.
April 2001, Bioorganic & medicinal chemistry,
A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production.
July 1996, Biochemical and biophysical research communications,
A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
A human inhibitor of tumor necrosis factor alpha.
April 1988, The Journal of experimental medicine,
A Pizarro, and A García-Tobaruela, and P Herranz, and J Pinilla
A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
October 2006, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!